Michael Brooks1, Guilherme Godoy1, Maxine Sun2, Shahrokh F Shariat3, Gilad E Amiel4, Seth P Lerner5. 1. Scott Department of Urology, Baylor College of Medicine, Houston, Texas. 2. University of Montreal Health Center, Montreal, Québec, Canada; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard School of Medicine, Boston, Massachusetts. 3. Bladder Cancer Research Consortium; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Weil Medical College Cornell University, New York, New York. 4. Bladder Cancer Research Consortium; Department of Urology, Rambam Health Care Campus, Haifa, Israel. 5. Scott Department of Urology, Baylor College of Medicine, Houston, Texas; Bladder Cancer Research Consortium. Electronic address: slerner@bcm.edu.
Abstract
PURPOSE: We externally validated 3 previously published nomograms to predicting recurrence, and cancer specific and overall survival following radical cystectomy and pelvic lymph node dissection for urothelial carcinoma of the bladder. MATERIALS AND METHODS: Two surgeons from a single institution performed a total of 197 consecutive radical cystectomies and pelvic lymph node dissections for bladder cancer from January 2003 to September 2009. A total of 23 patients were excluded from analysis. Examined parameters were those used in the original nomograms, including patient age, gender, pathological T stage, N stage, tumor grade, presence of carcinoma in situ and lymphovascular invasion, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiation therapy. Nomogram predictions were compared to actuarial outcomes and predictive accuracy was quantified using measures of discrimination and calibration. RESULTS: At the time of analysis 34 patients had experienced recurrence, of whom 28 died of disease and 6 were currently alive with disease. Discrimination at 2, 5 and 8 years was 0.776, 0.809 and 0.794 for recurrence, 0.822, 0.840 and 0.849 for cancer specific survival, and 0.812, 0.820 and 0.825, respectively, for overall survival. Calibration plots revealed nomogram overestimation of all 3 end points. CONCLUSIONS: Nomograms for bladder cancer recurrence, cancer specific survival and overall survival following radical cystectomy and pelvic lymph node dissection performed well in our series with accuracy comparable to that in the original series. The use of nomogram predictions should be further explored in clinical trials to assess the impact on patient care in clinical practice.
PURPOSE: We externally validated 3 previously published nomograms to predicting recurrence, and cancer specific and overall survival following radical cystectomy and pelvic lymph node dissection for urothelial carcinoma of the bladder. MATERIALS AND METHODS: Two surgeons from a single institution performed a total of 197 consecutive radical cystectomies and pelvic lymph node dissections for bladder cancer from January 2003 to September 2009. A total of 23 patients were excluded from analysis. Examined parameters were those used in the original nomograms, including patient age, gender, pathological T stage, N stage, tumor grade, presence of carcinoma in situ and lymphovascular invasion, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiation therapy. Nomogram predictions were compared to actuarial outcomes and predictive accuracy was quantified using measures of discrimination and calibration. RESULTS: At the time of analysis 34 patients had experienced recurrence, of whom 28 died of disease and 6 were currently alive with disease. Discrimination at 2, 5 and 8 years was 0.776, 0.809 and 0.794 for recurrence, 0.822, 0.840 and 0.849 for cancer specific survival, and 0.812, 0.820 and 0.825, respectively, for overall survival. Calibration plots revealed nomogram overestimation of all 3 end points. CONCLUSIONS: Nomograms for bladder cancer recurrence, cancer specific survival and overall survival following radical cystectomy and pelvic lymph node dissection performed well in our series with accuracy comparable to that in the original series. The use of nomogram predictions should be further explored in clinical trials to assess the impact on patient care in clinical practice.
Authors: Pierre I Karakiewicz; Shahrokh F Shariat; Ganesh S Palapattu; Amiel E Gilad; Yair Lotan; Craig G Rogers; Amnon Vazina; Amit Gupta; Patrick J Bastian; Paul Perrotte; Arthur I Sagalowsky; Mark Schoenberg; Seth P Lerner Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Gilad E Amiel; Yair Lotan; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Amit Gupta; Arthur I Sagalowsky; Mark Schoenberg; Seth P Lerner Journal: Clin Cancer Res Date: 2006-11-15 Impact factor: 12.531
Authors: Guru Sonpavde; Bryan H Goldman; V O Speights; Seth P Lerner; David P Wood; Nicholas J Vogelzang; Donald L Trump; Ronald B Natale; H Barton Grossman; E David Crawford Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Derya Tilki; Oliver Reich; Pierre I Karakiewicz; Giacomo Novara; Wassim Kassouf; Süleyman Ergün; Yves Fradet; Vincenzo Ficarra; Guru Sonpavde; Christian G Stief; Eila Skinner; Robert S Svatek; Yair Lotan; Arthur I Sagalowsky; Shahrokh F Shariat Journal: Eur Urol Date: 2010-01-20 Impact factor: 20.096
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Stephen B Williams; Jinhai Huo; Yiyi Chu; Jacques G Baillargeon; Timothy Daskivich; Yong-Fang Kuo; Christopher D Kosarek; Simon P Kim; Eduardo Orihuela; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat Journal: Urology Date: 2017-08-25 Impact factor: 2.649